Pivotal readout
Roche's satralizumab keeps most thyroid eye disease responders through week 48
Pooled 48-week data from two Phase 3 studies, SatraGO-1 and SatraGO-2, show that about 85% of week-24 responders on satralizumab (Enspryng) were still responding at week 48. Safety data raised no new concerns and showed no serious infections. The IL-6 receptor antibody won US approval for adults with thyroid eye disease last month and has been filed in China.
- Drugsatralizumab
- CompanyRoche
- TargetInterleukin-6 receptor subunit alpha
- TrialNCT05987423
- TrialNCT06106828
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.
